Analysts Offer Insights on Healthcare Companies: AveXis Inc (NASDAQ: AVXS), Cidara Therapeutics (NASDAQ: CDTX) and Eiger Biopharmaceuticals (NASDAQ: EIGR)

By Ryan Adsit

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on AveXis Inc (NASDAQ: AVXS), Cidara Therapeutics (NASDAQ: CDTX) and Eiger Biopharmaceuticals (NASDAQ: EIGR) with bullish sentiments.

AveXis Inc (NASDAQ: AVXS)

Jefferies analyst Biren Amin reiterated a Buy rating on AveXis Inc (NASDAQ: AVXS) yesterday and set a price target of $79. The company’s shares closed last Friday at $67.35, close to its 52-week high of $70.

Amin wrote:

“The EMA hosted a workshop on Friday to discuss pot’l trial designs for SMA Type 1 which may influence AVXS’ development plan in EU. We are more confident that EMA could follow FDA’s steps and approve on a single arm design trial so long as a significant effect is achieved over baseline on a motor milestone such as sitting in the pivotal study.”

According to TipRanks.com, Amin is a 4-star analyst with an average return of 6.1% and a 53.4% success rate. Amin covers the Healthcare sector, focusing on stocks such as Bellicum Pharmaceuticals, Anthera Pharmaceuticals, and Aquinox Pharmaceuticals.

Currently, the analyst consensus on AveXis Inc is Strong Buy and the average price target is $69.50, representing a 3.2% upside.

In a report issued on November 1, BMO Capital also reiterated a Buy rating on the stock.
Cidara Therapeutics (NASDAQ: CDTX)

Jefferies analyst Eun Yang reiterated a Buy rating on Cidara Therapeutics (NASDAQ: CDTX) on November 11 and set a price target of $25. The company’s shares closed last Friday at $11.50.

Yang wrote:

“In line 3Q16 net loss; cash of ~$79M at end-3Q16 and follow-on public offering of~$28M sufficient into ~2018 by estimates. Ph2 trials of CD101 topical in VVC and CD101 IV in candidemia are under way with potential data in 1Q17 and 4Q17, respectively.”

According to TipRanks.com, Yang is a 4-star analyst with an average return of 2.4% and a 56.8% success rate. Yang covers the Healthcare sector, focusing on stocks such as DBV Technologies S.A. – American, Achillion Pharmaceuticals, and Ionis Pharmaceuticals Inc.

Currently, the analyst consensus on Cidara Therapeutics is Moderate Buy and the average price target is $19.50, representing a 69.6% upside.

In a report issued on November 11, Cantor Fitzgerald also reiterated a Buy rating on the stock with a $20 price target.
Eiger Biopharmaceuticals (NASDAQ: EIGR)

In a report issued on November 11, Brian Abrahams from Jefferies reiterated a Buy rating on Eiger Biopharmaceuticals (NASDAQ: EIGR), with a price target of $28. The company’s shares closed last Friday at $13.50.

Abrahams wrote:

“The appearance on clinicaltrials.gov of a previously-undisclosed trial in the lonafarnib HDV clinical plan, which appears to assess impact on VL and histology over longer treatment, may hint at the direction of their ultimate registrational plan and at what we believe will continue to be positive efficacy/ safety data presented for the drug at AASLD in the coming days.”

According to TipRanks.com, Abrahams is a 5-star analyst with an average return of 6.6% and a 60.8% success rate. Abrahams covers the Healthcare sector, focusing on stocks such as DBV Technologies S.A. – American, Achillion Pharmaceuticals, and Protalix Biotherapeutics.

Eiger Biopharmaceuticals has an analyst consensus of Moderate Buy, with a price target consensus of $28.